Fortis Memorial Research Institute in Gurugram has launched a trial run of the Sputnik V COVID-19 vaccine for the public, news agency ANI reported on June 27.
The made-in-Russia jab was the third vaccine to be granted regulatory clearance in India, in April this year. The vaccine's soft-launched was initiated in May by pharmaceutical firm Dr Reddy's Laboratories.
The two doses of Sputnik V are required to be administered at an interval of 21 days. Both the doses are different and not interchangeable.
The reports of public trial of Sputnik V, being launched at Fortis Memorial facility in Gurugram, came shortly after several hospitals in Delhi-NCR claimed that the vaccine's rollout has been further delayed.
"We do not have clarity on the dates of the vaccine roll-out," news agency PTI quoted a spokesman of Apollo Hospitals as saying. An official of Madhukar Rainbow Children's Hospital also said that the facility has also not received Sputnik V doses so far from Hyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country.
Notably, Sputnik V has been developed by Russia's Gamaleya National Research Institute of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) is marketing it globally.
Dr Reddy's Laboratories has been importing the shots from Russia. Over a period of time, the vaccine is also going to be manufactured in India. The central government has fixed the price of the vaccine at Rs 1,145 per dose.
According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 percent.